Medical Affairs-Liver at Gilead Sciences

Tokyo, Japan

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Pharmaceuticals, Biotechnology, HealthcareIndustries

Requirements

Minimum 3 years of industry experience
Strong written and verbal communication skills in both Japanese and English, with sound judgment and ability to work effectively in a team environment
Hands-on approach with effective use of external resources
High learning agility
Advanced degree in life science (PhD, Pharm D, MD) with clinical and research experience (desirable)
Experience in medical, MSL or R&D in Liver disease area (desirable)
Demonstrated leadership in ambiguous situations (desirable)
Project Management Skills (desirable)

Responsibilities

Build and maintain strong relationships with Liver KOLs and other key external stakeholders and be recognized as an innovative and valuable partner in improving care for hepatitis patients
Engage in regular communication with Liver KOLs to provide medical insights, background information, additional data, and responses to scientific or commercial inquiries
Attend major conferences, coordinate medical affairs activities, and present to external audiences as needed
Maintain up-to-date clinical, scientific, and technical expertise in liver disease
Manage assigned projects to completion, proactively identifying and resolving challenges in a collaborative manner
Ensure all interactions and activities comply with corporate compliance policies, industry codes of conduct, and regulations, including responses to unsolicited medical/scientific requests
Lead planning and execution of the Liver Plan of Action (POA), including data generation, publications, and medical education programs, in collaboration with the Liver medical team and partners
Maintain clinical, scientific, and technical expertise in Liver disease area to develop and conduct strategic medical activities
Collaborate effectively with cross-functional teams including clinical, regulatory, commercial on initiatives such as publication planning and speaker education programs, advisory meetings
Provide scientific and medical guidance throughout the product lifecycle, with close collaboration and communication with Japan Medical Affairs, Global/Asia Medical Affairs, and other key functions

Skills

Medical Affairs

KOL Engagement

Hepatitis

Liver Disease

Scientific Communication

Stakeholder Management

Product Lifecycle

Medical Insights

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Gilead Sciences focuses on discovering, developing, and commercializing medicines for various medical conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its operations and product offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Foster City, CaliforniaHeadquarters

1987Year Founded

$15,873.6MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Risks

Increased competition in HIV treatment from ViiV Healthcare's expanding drug portfolio.

Regulatory scrutiny over drug pricing could impact Gilead's U.S. market operations.

Patent expirations, like Truvada's, lead to increased generic competition and revenue loss.

Differentiation

Gilead's lenacapavir is recognized as the 2024 Breakthrough of the Year for HIV care.

Partnerships with LEO Pharma and Tubulis enhance Gilead's focus on inflammatory and cancer therapies.

Gilead's commitment to health equity initiatives like COMPASS and HepConnect sets it apart.

Upsides

Gilead's strategic partnerships expand its reach in inflammatory and oncology drug markets.

Investment in digital health technologies enhances Gilead's R&D and patient engagement.

Focus on sustainability improves Gilead's operational efficiency and corporate reputation.

Land your dream remote job 3x faster with AI

Try Jobo Free